[222 Pages Report] The global oral controlled release drug delivery technology market is poised to grow from US$ 34.1 billion in 2022 to US$ 68.4 billion by 2032, with overall demand expected to surge at 7.2% CAGR throughout the forecast period (2022 to 2032). The rising incidence of chronic diseases coupled with a growing preference for oral drug delivery due to its various benefits is the key factor driving demand for oral controlled-release drug delivery technology.
Based on form, the solid dosage forms segment is expected to lead the global oral controlled release drug delivery technology market throughout the forecast period with an estimated share of nearly 87%.
| Attribute | Key Statistics |
|---|---|
| Oral Controlled Release Drug Delivery Technology Market Base Value (2021) | US$ 31.8 billion |
| Estimated Market Value (2022) | US$ 34.1 billion |
| Projected Market Value (2032) | US$ 68.4 billion |
| Value-based CAGR (2022 to 2032) | 7.2% |
| Market share of Top 5 countries | 62.1% |
The oral controlled release drug delivery system is designed to deliver a drug in a controlled and predictable manner over a period of time or at a predetermined position in the gastrointestinal tract. Oral dosage forms are preferred for their convenience and cost-effectiveness.
Oral controlled release drug delivery technologies like, Geolock, Geomatrix, OROS (osmotic-controlled release drug delivery system), SODAS (Spheroidal oral drug absorption system), and many more are exclusively used for most of the pharmaceutical drug candidates and are the most common form to deliver medication to patients.
Oral solid dosage forms coupled with new drug releases mechanisms such as dissolution and diffusion-controlled drug release delivery systems are expected to remain a mainstay in the global pharmaceuticals market as these type of new and enhanced drug delivery systems with the use of advanced polymers tend to be an important part of drug development technology and approvals of new chemical entities.
The overall oral controlled release drug delivery technology market formed nearly 14% of the global pharmaceutical drug delivery market which was valued at around US$ 230 billion in 2021
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales in the oral controlled release drug delivery technology market are projected to rise at 7.2% CAGR during the forecast period between 2022 to 2032, in comparison to 6.5% CAGR registered from 2012 to 2021.
Growing demand for specialized oral dosage forms such as pediatric or geriatric tablets with controlled release drug delivery systems, the adoption rate of newly developed and innovative technologies such as nanotechnology, osmotically controlled release, hydrophilic ion exchange, etc. are the prime factors expected to drive the growth of oral controlled release drug delivery technology market over the forecast period.
Oral drug delivery has become the most preferred and convenient option as the oral route provides maximum active surface area among all drug delivery systems for the administration of various drugs.
Increasing generic penetration is another important factor pushing the growth of the global market. Oral solid dosage forms such as tablets and capsules represent the largest growth opportunity for generic players.
Some other factors influencing the growth of the global oral controlled release drug delivery technology market include cost-effective generic dosage forms, Research and Development (R&D) scientists, and healthcare professionals’ preference for sustained release controlled delivery coupled with new biopolymers embedded with advanced coating technology in solid dosage forms, liquids, and semisolids.
Furthermore, the combination of various technologies to overcome the limitations of poorly soluble substances/drugs/chemicals and the higher adoption rate of these combined products/technologies at convenient pricing is expected to boost the oral controlled release drug delivery technology market.
In addition to this, increasing approval of modified and extended-release oral dosage forms by various health ministries across the world is likely to drive the market.
The rise in Chronic Diseases and Advancement in Drug Delivery Techniques to Boost Market Growth
As per FMI, the global oral controlled release drug delivery technology market is projected to expand at a robust pace during the forecast period, owing to the rising prevalence of chronic and infectious diseases like cancer, T.B. heart disease, diabetes, etc., and increasing spending on oral medications.
Similarly, continuous efforts of manufacturers to develop and produce novel complex drug products with customized release trends will propel the expansion of the oral controlled release drug delivery technology market globally during the forecast years.
Use of combination techniques such as modified controlled release mechanisms and other platforms which uses ion exchange release (hydrophilic & hydrophobic), osmotically controlled release, diffusion & dissolution (combined) controlled release in new drug formulation procedures is on the rise across the healthcare industry and the trend is likely to continue during the forecast period.
Also, the introduction of super generics, continuous new technology launches, and a growing number of contract manufacturing facilities for oral solid dosage forms & liquid dosage forms, and enhanced patient compliance are expected to create lucrative market growth opportunities during the forecast period.
According to research published in the Journal of Controlled Release, it has been found that ‘casein’ based formulations are probable contenders for controlled release drug delivery systems, because of their properties like high tensile strength and presence of naturally occurring genipin, tissue enzyme & transglutaminase. Casein can also be used as a cross-linkers to prepare novel casein-based hydrogels for the controlled release of bioactive.
Similarly, the growing usage of 3D printing technology for designing and manufacturing oral formulations is expected to create lucrative opportunities for oral controlled-release drug delivery system manufacturers.
3D printing techniques can be used to produce multiple doses of drugs at a small scale and to improve drug formulations. 3D printing technology can be a great prospect for manufacturers to impose in their innovative, research and development department for drug formulations.
Principal Consultant
Formulation challenges are mainly drug-related - active pharmaceutical ingredients with a short half-life and the necessity for higher-dose delivery and formulation related, which regularly require dissolvable handling capacities in light of the fact that most polymers should be solubilized in natural solvents before covering the controlled-release formulations (i.e., tablets, granules, and capsules)
Growing research towards biological molecules and their dominance in treating oncology conditions are expected to hamper the growth of the oral controlled release drug delivery technology market over the forecast period.
According to an article published in Contract pharma, approximately 50% of the pipeline molecules are biologics and the rest are in the form of other dosage forms.
However, the low pipeline productivity of oral solids is the major factor hindering the growth of the oral controlled-release drug delivery technology market.
Other factors include a complex supply chain and stringent regulatory requirements, decreasing productivity coupled with low R&D expenditure, product related issues such as dose dumping and product recalls.
Rising Spending on Medicines Fuelling Market Growth in the USA
The USA oral controlled release drug delivery technology market reached a valuation of over US$ 11.0 billion in 2021 and is expected to grow over a CAGR of 7.0% during the forecast period (2022 to 2032).
The rising prevalence of chronic diseases such as cancer and diabetes, supporting initiatives & campaigns from the government, and investments in research & development are driving b growth in the USA market and the trend is likely to continue during the forecast period.
Similarly, the strong presence of major key players in the country and their promotional strategies for the adoption of controlled release drug delivery systems are expected to expand the oral controlled release drug delivery technology market in the future.
In addition to this, increasing spending on medicines across the country will create opportunities for oral controlled-release drug delivery technology manufacturers in the future. In fact, the USA is the highest spending country worldwide when it comes to health care.
According to the USA Department of Health and Human Services, USA prescription drug expenditures totaled an enormous valuation of US$370 billion in 2019 and this number is likely to further surge during the assessment period.
Rising Prevalence of Heart Diseases Driving Demand Across Germany
As of 2021, Germany held a revenue share of 21.5% of total European oral controlled release drug delivery technology market and it is estimated to grow at a healthy pace during the forecast period.
The German oral controlled release drug delivery technology market will likely be driven by improved patient compliance, rising geriatric and paediatric populations, and increased demand for controlled release drug delivery systems due to the prevalence of chronic diseases.
Over the years, there has been a sharp rise in cases of heart disease across Germany leading to a high death rate. Oral solid dosages are utilized very commonly for the treatment of the same. As per the World Health Organization (WHO) insights in 2019, nearly 37% of deaths in Germany were due to circulatory diseases.
Thus, the growing demand for oral solid dosage together with the rising prevalence of circulatory disease is expected to boost Germany’s oral controlled release drug delivery technology market during the next ten years.
Growing Preference for Oral Medication Fostering Market Growth in Japan
The overall oral controlled release drug delivery technology market in Japan reached US$ 2.6 billion in 2021 and it is expected to expand at a CAGR of around 6.7% during the forecast period. This can be attributed to the rising popularity of oral medication among the country’s rapidly growing population, advancements in the pharmaceutical sector, and increasing investments in R&D activities by biopharma companies.
Similarly, increasing healthcare spending and high levels of health awareness among the general public are expected to bolster the growth of the oral controlled release drug delivery technology market in Japan during the forthcoming years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand Remains High for Dissolution Controlled Release System
The dissolution controlled release system segment dominated the global oral controlled release drug delivery technology market with a revenue share of nearly 45% in 2021 and the trend is projected to continue throughout the forecast period.
Properties such as maximum efficacy with minimal side effects and reduced drug accumulation with drug level fluctuation are the major reasons for the adoption of this technique.
The dissolution controlled release system provides sustained release profiles i.e., In a dissolution controlled release system, the active drugs are released continuously at a slow rate to provide a long-term therapeutic effect. Thus, they provide a sustained release profile, which is encouraging their adoption across the world.
End Users Prefer Solid Dosage Forms
As per FMI, the solid dosage forms segment generated revenue of around US$ 27 billion in the global oral controlled release drug delivery technology market in 2021 and it is poised to grow at a higher CAGR over the next ten years. This can be attributed to the rising end-user preference for solid dosage forms.
Owing to the better physical and chemical stability, lower manufacturing costs, and easy-to-consume & carry features of solid dosage forms, it remains highly popular among end users. People are increasingly opting for solid dosage forms like tablets, capsules, and powders to treat various diseases.
Some of the key players identified in global oral controlled release drug delivery technology market are AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co. Inc., Novartis AG, Pfizer Inc., F. Hoffman-La-Roche Ltd., and Johnson & Johnson.
These players are trying to combine new molecular entities with existing ones to explore clinical indications for controlled release mechanisms, which in turn is propelling the discovery of new matrix systems in the oral controlled release drug delivery technology market. Furthermore, they are partnering and collaborating with other companies to increase their revenue share. For instance,
| Attribute | Details |
|---|---|
| Estimated Market Size (2022) | US$ 34.1 billion |
| Projected Market Size (2032) | US$ 68.4 billion |
| Anticipated Growth Rate (2022 to 2032) | 7.2% |
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2012 to 2021 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA). |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, the Rest of Latin America, The United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, the Rest of Europe, Japan, China, South Korea, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Australia, New Zealand, Turkey, GCC, South Africa, Israel, North Africa and Rest of MEA. |
| Key Market Segments Covered | Drug Release System, Dosage Form, Region |
| Key Companies Profiled | AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co. Inc., Novartis AG, Pfizer Inc., F. Hoffman-La-Roche Ltd., Johnson & Johnson, GlaxoSmithKline Plc., Sun Pharmaceuticals, Sanofi S.A., Boehringer Ingelheim, AbbVie, Takeda, Eli Lilly, Bayer, Gilead Sciences, Amgen, BioNTech, Viatris, Moderna. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The global oral controlled release drug delivery technology market is estimated to be valued at US$ 34.1 billion in 2022.
The global oral controlled release drug delivery technology market is anticipated to reach a valuation of about US$ 68.4 billion by the end of 2032.
As per FMI, the global oral controlled release drug delivery technology market is expected to grow at around 7.2% CAGR during the forecast period.
North America will continue to dominate the global oral controlled release drug delivery technology, exhibiting a growth rate of 6.9% CAGR throughout the forecast period.
With a valuation of nearly US$ 27 Billion in 2021, the solid dosage forms segment will continue to lead the global oral controlled release drug delivery technology market.
AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co. Inc., Novartis AG, Pfizer Inc., F. Hoffman-La-Roche Ltd., Johnson & Johnson, GlaxoSmithKline Plc., and Sun Pharmaceuticals are the major players operating in the global market.
Increasing adoption rates of the newer technologies, growing incidence of chronic diseases, increasing geriatric & paediatric population, and investments in research & development activities are some of the major factors driving the global oral controlled release drug delivery technology market.
1. Executive Summary | Oral Controlled Release Drug Delivery Technology Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology, by Region
4.2. Key promotional strategies by manufacturers
4.3. Regulatory Landscape
4.4. Value chain analysis
4.5. Drug Release System adoption analysis
4.6. PESTEL Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. Increasing Complexity of Healthcare Operations
5.2.3. Drug Release System Pricing
5.2.4. Strategic Collaborations amongst Players
5.2.5. Rising Prevalence of Infections and Surgical Procedures
5.2.6. Adoption Rate
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID 002D19 and Impact Analysis
6.1.1. By Drug Release System
6.1.2. By Dosage Form
6.1.3. By Country
6.2. 2021 Market Scenario
7. Global Oral Controlled Release Drug Delivery Technology Market Demand (in Value) Analysis 2012 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ million) Analysis, 2012 to 2021
7.2. Current and Future Market Value (US$ million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug Release System
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ million) Analysis, By Drug Release System, 2012 to 2021
8.3. Current and Future Market Size (US$ million) Analysis and Forecast, By Drug Release System, 2022 to 2032
8.3.1. Dissolution Controlled Release System
8.3.2. Diffusion Controlled Release System
8.3.3. Osmotically Controlled Release System
8.3.4. Dissolution & Diffusion Controlled Release System
8.3.5. Ion Exchange Resins Controlled Release
8.3.6. Hydrodynamically Balanced Drug Delivery System
8.3.7. Others
8.4. Market Attractiveness Analysis, by Drug Release System
9. Global Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ million) Analysis, By Dosage Form, 2012 to 2021
9.3. Current and Future Market Size (US$ million) Analysis and Forecast, by Dosage Form, 2022 to 2032
9.3.1. Solid Dosage Form
9.3.2. Semisolid/Liquid/Suspensions
9.4. Market Attractiveness Analysis, by Dosage Form
10. Global Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region
10.1. Introduction
10.2. Historical Market Size (US$ million) Analysis, by Region, 2012 to 2021
10.3. Current and Future Market Value (US$ million) Projections, 2022 to 2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis, by Region
11. North America Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032
11.1. Introduction
11.2. Historical Market Size (US$ million) and Volume (Unit) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021
11.3. Current and Future Market Value (US$ million) and Volume (Unit) Projections, 2022 to 2032
11.3.1. By Country
11.3.1.1. The USA
11.3.1.2. Canada
11.3.2. By Drug Release System
11.3.3. By Dosage Form
11.3.4. By Distribution Channel
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Drug Release System
11.4.3. By Dosage Form
11.5. Market Trends
11.6. Drivers and Restraints - Impact Analysis
11.7. Country Level Analysis & Forecast
11.7.1. The USA Oral Controlled Release Drug Delivery Technology Market Analysis
11.7.1.1. Introduction
11.7.1.2. Market Analysis and Forecast, by Market Taxonomy
11.7.1.2.1. By Drug Release System
11.7.1.2.2. By Dosage Form
11.7.2. Canada Oral Controlled Release Drug Delivery Technology Market Analysis
11.7.2.1. Introduction
11.7.2.2. Market Analysis and Forecast, by Market Taxonomy
11.7.2.2.1. By Drug Release System
11.7.2.2.2. By Dosage Form
12. Latin America Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032
12.1. Introduction
12.2. Historical Market Size (US$ million) Trend Analysis, by Market Taxonomy, 2012 to 2021
12.3. Current and Future Market Value (US$ million) Projections, 2022 to 2032
12.3.1. By Country
12.3.1.1. Mexico
12.3.1.2. Brazil
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Drug Release System
12.3.3. By Dosage Form
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Drug Release System
12.4.3. By Dosage Form
12.5. Market Trends
12.6. Drivers and Restraints - Impact Analysis
12.7. Country Level Analysis & Forecast
12.7.1. Mexico Oral Controlled Release Drug Delivery Technology Market Analysis
12.7.1.1. Introduction
12.7.1.2. Market Analysis and Forecast, by Market Taxonomy
12.7.1.2.1. By Drug Release System
12.7.1.2.2. By Dosage Form
12.7.2. Brazil Oral Controlled Release Drug Delivery Technology Market Analysis
12.7.2.1. Introduction
12.7.2.2. Market Analysis and Forecast, by Market Taxonomy
12.7.2.2.1. By Drug Release System
12.7.2.2.2. By Dosage Form
12.7.3. Argentina Oral Controlled Release Drug Delivery Technology Market Analysis
12.7.3.1. Introduction
12.7.3.2. Market Analysis and Forecast, by Market Taxonomy
12.7.3.2.1. By Drug Release System
12.7.3.2.2. By Dosage Form
13. Europe Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Historical Market Size (US$ million) Trend Analysis, by Market Taxonomy, 2012 to 2021
13.3. Current and Future Market Value (US$ million) Projections, 2022 to 2032
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Rest of Europe
13.3.2. By Drug Release System
13.3.3. By Dosage Form
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Release System
13.4.3. By Dosage Form
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Country Level Analysis & Forecast
13.7.1. Germany Oral Controlled Release Drug Delivery Technology Market Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast, by Market Taxonomy
13.7.1.2.1. By Drug Release System
13.7.1.2.2. By Dosage Form
13.7.2. Italy Oral Controlled Release Drug Delivery Technology Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast, by Market Taxonomy
13.7.2.2.1. By Drug Release System
13.7.2.2.2. By Dosage Form
13.7.3. France Oral Controlled Release Drug Delivery Technology Market Analysis
13.7.3.1. Introduction
13.7.3.2. Market Analysis and Forecast, by Market Taxonomy
13.7.3.2.1. By Drug Release System
13.7.3.2.2. By Dosage Form
13.7.4. U.K. Oral Controlled Release Drug Delivery Technology Market Analysis
13.7.4.1. Introduction
13.7.4.2. Market Analysis and Forecast, by Market Taxonomy
13.7.4.2.1. By Drug Release System
13.7.4.2.2. By Dosage Form
13.7.5. Spain Oral Controlled Release Drug Delivery Technology Market Analysis
13.7.5.1. Introduction
13.7.5.2. Market Analysis and Forecast, by Market Taxonomy
13.7.5.2.1. By Drug Release System
13.7.5.2.2. By Dosage Form
13.7.6. BENELUX Oral Controlled Release Drug Delivery Technology Market Analysis
13.7.6.1. Introduction
13.7.6.2. Market Analysis and Forecast, by Market Taxonomy
13.7.6.2.1. By Drug Release System
13.7.6.2.2. By Dosage Form
13.7.7. Russia Oral Controlled Release Drug Delivery Technology Market Analysis
13.7.7.1. Introduction
13.7.7.2. Market Analysis and Forecast, by Market Taxonomy
13.7.7.2.1. By Drug Release System
13.7.7.2.2. By Dosage Form
14. East Asia Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Historical Market Distribution Channel (US$ million) Trend Analysis, by Market Taxonomy, 2012 to 2021
14.3. Current and Future Market Value (US$ million) Projections, 2022 to 2032
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Drug Release System
14.3.3. By Dosage Form
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Release System
14.4.3. By Dosage Form
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Country Level Analysis & Forecast
14.7.1. China Oral Controlled Release Drug Delivery Technology Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast, by Market Taxonomy
14.7.1.2.1. By Drug Release System
14.7.1.2.2. By Dosage Form
14.7.2. Japan Oral Controlled Release Drug Delivery Technology Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast, by Market Taxonomy
14.7.2.2.1. By Drug Release System
14.7.2.2.2. By Dosage Form
14.7.3. South Korea Oral Controlled Release Drug Delivery Technology Market Analysis
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast, by Market Taxonomy
14.7.3.2.1. By Drug Release System
14.7.3.2.2. By Dosage Form
15. South Asia Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Historical Market Size (US$ million) Trend Analysis, by Market Taxonomy, 2012 to 2021
15.3. Current and Future Market Value (US$ million) Projections, 2022 to 2032
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Indonesia
15.3.1.3. Malaysia
15.3.1.4. Thailand
15.3.1.5. Rest of South Asia
15.3.2. By Drug Release System
15.3.3. By Dosage Form
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Release System
15.4.3. By Dosage Form
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. India Oral Controlled Release Drug Delivery Technology Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast, by Market Taxonomy
15.7.1.2.1. By Drug Release System
15.7.1.2.2. By Dosage Form
15.7.2. Indonesia Oral Controlled Release Drug Delivery Technology Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast, by Market Taxonomy
15.7.2.2.1. By Drug Release System
15.7.2.2.2. By Dosage Form
15.7.3. Malaysia Oral Controlled Release Drug Delivery Technology Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast, by Market Taxonomy
15.7.3.2.1. By Drug Release System
15.7.3.2.2. By Dosage Form
15.7.4. Thailand Oral Controlled Release Drug Delivery Technology Market Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast, by Market Taxonomy
15.7.4.2.1. By Drug Release System
15.7.4.2.2. By Dosage Form
16. Oceania Oral Controlled Release Drug Delivery Technology Market 2012-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Historical Market Size (US$ million) Trend Analysis, by Market Taxonomy, 2012 to 2021
16.3. Current and Future Market Value (US$ million) Projections, 2022 to 2032
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Drug Release System
16.3.3. By Dosage Form
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Release System
16.4.3. By Dosage Form
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. Australia Oral Controlled Release Drug Delivery Technology Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast, by Market Taxonomy
16.7.1.2.1. By Drug Release System
16.7.1.2.2. By Dosage Form
16.7.2. New Zealand Oral Controlled Release Drug Delivery Technology Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast, by Market Taxonomy
16.7.2.2.1. By Drug Release System
16.7.2.2.2. By Dosage Form
17. Middle East and Africa (MEA) Oral Controlled Release Drug Delivery Technology Market Analysis 2012 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Historical Market Size (US$ million) Trend Analysis, by Market Taxonomy, 2012 to 2021
17.3. Current and Future Market Value (US$ million) Projections, 2022 to 2032
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Turkey
17.3.1.3. South Africa
17.3.1.4. Israel
17.3.1.5. North Africa
17.3.1.6. Rest of Middle East and Africa
17.3.2. By Drug Release System
17.3.3. By Dosage Form
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Release System
17.4.3. By Dosage Form
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country-Level Analysis & Forecast
17.7.1. GCC Countries Oral Controlled Release Drug Delivery Technology Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast, by Market Taxonomy
17.7.1.2.1. By Drug Release System
17.7.1.2.2. By Dosage Form
17.7.2. Turkey Oral Controlled Release Drug Delivery Technology Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast, by Market Taxonomy
17.7.2.2.1. By Drug Release System
17.7.2.2.2. By Dosage Form
17.7.3. South Africa Oral Controlled Release Drug Delivery Technology Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast, by Market Taxonomy
17.7.3.2.1. By Drug Release System
17.7.3.2.2. By Dosage Form
17.7.4. Israel Oral Controlled Release Drug Delivery Technology Market Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast, by Market Taxonomy
17.7.4.2.1. By Drug Release System
17.7.4.2.2. By Dosage Form
17.7.5. North Africa Oral Controlled Release Drug Delivery Technology Market
17.7.5.1. Introduction
17.7.5.2. Market Analysis and Forecast, by Market Taxonomy
17.7.5.2.1. By Drug Release System
17.7.5.2.2. By Dosage Form
18. Market Structure Analysis
18.1. Market Analysis, by Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Market Presence Analysis
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
19.3.1. AstraZeneca Plc.
19.3.1.1. Overview
19.3.1.2. Drug Release System Portfolio
19.3.1.3. Profitability by Market Segments (Product/Channel/Region)
19.3.1.4. Sales Footprint
19.3.1.5. Key Financials
19.3.1.6. SWOT Analysis
19.3.1.7. Strategy Overview
19.3.2. Bristol-Myers Squibb Company
19.3.2.1. Overview
19.3.2.2. Drug Release System Portfolio
19.3.2.3. Profitability by Market Segments (Product/Channel/Region)
19.3.2.4. Sales Footprint
19.3.2.5. Key Financials
19.3.2.6. SWOT Analysis
19.3.2.7. Strategy Overview
19.3.3. Merck & Co. Inc.
19.3.3.1. Overview
19.3.3.2. Drug Release System Portfolio
19.3.3.3. Profitability by Market Segments (Product/Channel/Region)
19.3.3.4. Sales Footprint
19.3.3.5. Key Financials
19.3.3.6. SWOT Analysis
19.3.3.7. Strategy Overview
19.3.4. Novartis AG
19.3.4.1. Overview
19.3.4.2. Drug Release System Portfolio
19.3.4.3. Profitability by Market Segments (Product/Channel/Region)
19.3.4.4. Sales Footprint
19.3.4.5. Key Financials
19.3.4.6. SWOT Analysis
19.3.4.7. Strategy Overview
19.3.5. Pfizer Inc.
19.3.5.1. Overview
19.3.5.2. Drug Release System Portfolio
19.3.5.3. Profitability by Market Segments (Product/Channel/Region)
19.3.5.4. Sales Footprint
19.3.5.5. Key Financials
19.3.5.6. SWOT Analysis
19.3.5.7. Strategy Overview
19.3.6. F. Hoffman-La-Roche Ltd.
19.3.6.1. Overview
19.3.6.2. Drug Release System Portfolio
19.3.6.3. Profitability by Market Segments (Product/Channel/Region)
19.3.6.4. Sales Footprint
19.3.6.5. Key Financials
19.3.6.6. SWOT Analysis
19.3.6.7. Strategy Overview
19.3.7. Johnson & Johnson
19.3.7.1. Overview
19.3.7.2. Drug Release System Portfolio
19.3.7.3. Profitability by Market Segments (Product/Channel/Region)
19.3.7.4. Sales Footprint
19.3.7.5. Key Financials
19.3.7.6. SWOT Analysis
19.3.7.7. Strategy Overview
19.3.8. GlaxoSmithKline Plc.
19.3.8.1. Overview
19.3.8.2. Drug Release System Portfolio
19.3.8.3. Profitability by Market Segments (Product/Channel/Region)
19.3.8.4. Sales Footprint
19.3.8.5. Key Financials
19.3.8.6. SWOT Analysis
19.3.8.7. Strategy Overview
19.3.9. Sun Pharmaceuticals
19.3.9.1. Overview
19.3.9.2. Drug Release System Portfolio
19.3.9.3. Profitability by Market Segments (Product/Channel/Region)
19.3.9.4. Sales Footprint
19.3.9.5. Key Financials
19.3.9.6. SWOT Analysis
19.3.9.7. Strategy Overview
19.3.10. Sanofi S.A.
19.3.10.1. Overview
19.3.10.2. Drug Release System Portfolio
19.3.10.3. Profitability by Market Segments (Product/Channel/Region)
19.3.10.4. Sales Footprint
19.3.10.5. Key Financials
19.3.10.6. SWOT Analysis
19.3.10.7. Strategy Overview
19.3.11. Boehringer Ingelheim
19.3.11.1. Overview
19.3.11.2. Drug Release System Portfolio
19.3.11.3. Profitability by Market Segments (Product/Channel/Region)
19.3.11.4. Sales Footprint
19.3.11.5. Key Financials
19.3.11.6. SWOT Analysis
19.3.11.7. Strategy Overview
19.3.12. AbbVie
19.3.12.1. Overview
19.3.12.2. Drug Release System Portfolio
19.3.12.3. Profitability by Market Segments (Product/Channel/Region)
19.3.12.4. Sales Footprint
19.3.12.5. Key Financials
19.3.12.6. SWOT Analysis
19.3.12.7. Strategy Overview
19.3.13. Takeda
19.3.13.1. Overview
19.3.13.2. Drug Release System Portfolio
19.3.13.3. Profitability by Market Segments (Product/Channel/Region)
19.3.13.4. Sales Footprint
19.3.13.5. Key Financials
19.3.13.6. SWOT Analysis
19.3.13.7. Strategy Overview
19.3.14. Eli Lilly
19.3.14.1. Overview
19.3.14.2. Drug Release System Portfolio
19.3.14.3. Profitability by Market Segments (Product/Channel/Region)
19.3.14.4. Sales Footprint
19.3.14.5. Key Financials
19.3.14.6. SWOT Analysis
19.3.14.7. Strategy Overview
19.3.15. Bayer
19.3.15.1. Overview
19.3.15.2. Drug Release System Portfolio
19.3.15.3. Profitability by Market Segments (Product/Channel/Region)
19.3.15.4. Sales Footprint
19.3.15.5. Key Financials
19.3.15.6. SWOT Analysis
19.3.15.7. Strategy Overview
19.3.16. Gilead Sciences
19.3.16.1. Overview
19.3.16.2. Drug Release System Portfolio
19.3.16.3. Profitability by Market Segments (Product/Channel/Region)
19.3.16.4. Sales Footprint
19.3.16.5. Key Financials
19.3.16.6. SWOT Analysis
19.3.16.7. Strategy Overview
19.3.17. Amgen
19.3.17.1. Overview
19.3.17.2. Drug Release System Portfolio
19.3.17.3. Profitability by Market Segments (Product/Channel/Region)
19.3.17.4. Sales Footprint
19.3.17.5. Key Financials
19.3.17.6. SWOT Analysis
19.3.17.7. Strategy Overview
19.3.18. BioNTech
19.3.18.1. Overview
19.3.18.2. Drug Release System Portfolio
19.3.18.3. Profitability by Market Segments (Product/Channel/Region)
19.3.18.4. Sales Footprint
19.3.18.5. Key Financials
19.3.18.6. SWOT Analysis
19.3.18.7. Strategy Overview
19.3.19. Viatris
19.3.19.1. Overview
19.3.19.2. Drug Release System Portfolio
19.3.19.3. Profitability by Market Segments (Product/Channel/Region)
19.3.19.4. Sales Footprint
19.3.19.5. Key Financials
19.3.19.6. SWOT Analysis
19.3.19.7. Strategy Overview
19.3.20. Moderna
19.3.20.1. Overview
19.3.20.2. Drug Release System Portfolio
19.3.20.3. Profitability by Market Segments (Product/Channel/Region)
19.3.20.4. Sales Footprint
19.3.20.5. Key Financials
19.3.20.6. SWOT Analysis
19.3.20.7. Strategy Overview
20. Assumptions and Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Oral Controlled Release Drug Delivery Technology Market
